1 published article · Updated continuously
15 trials tracked for Dyspepsia: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 87 citations.
Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Pharmacological management of dyspepsia includes the use of Compound Sodium Alginate Double Action Chewable Tablets, which demonstrated significant improvements in the Reflux Disease Questionnaire (RDQ) scores across multiple dimensions: GERD (-1.06 to -1.27; p<0.0001), Dyspepsia (-0.80 to -0.98; p=0.0004), and Heartburn (-0.95 to -1.16; p=0.0001) 7.
Treatment of H. pylori infection, a factor relevant in dyspepsia management, was shown to be effective with RHB-105, which demonstrated significant eradication rates in multiple trials (6, 8). Other established pharmacological interventions for related conditions include Pantoprazole 3 and Omeprazole 4.
Clinical trials evaluating Kolofort showed a statistically significant reduction in the severity of functional dyspepsia (FD) symptoms (p=0.041), although changes in the Nepean Dyspepsia Index (NDI) did not reach statistical significance (p=0.435) 2.
AI synthesis of 7 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
